I appreciate your insight Mr. Greenwald but I disagree you on one matter. The following statement is inaccurate: "Finally, the filing notes that if TTP399 passes the trial phase G42 Investments will be given the right to purchase an additional USD 30 million in stock from vTv Therapeutics."
The correction is as follows from the License Agreement between Vtv Therapeutics & G42 Investments on page 11:
"the Company shall issue to the Purchaser as payment for the services provided by or on behalf of the G42 Counterparty under the Collaboration and License Agreement a number of newly-issued shares of Common Stock (such newly-issued shares, the “Milestone Shares”) equal to the quotient of (A) $30,000,000 divided by (B) the greater of (1) $1.20 and (2) the volume-weighted average price per share of Common Stock on the Nasdaq Capital Market as such daily volume-weighted average price per share is reported by Bloomberg L.P. (or, if such information is no longer reported by Bloomberg L.P., as reported by a comparable internationally recognized source reasonably determined by the Company) calculated for the twenty (20) consecutive trading days immediately following (but not including) the date the Company receives notice of the FDA Approval (rounded down to the nearest whole share); provided that, within thirty (30) days following the FDA Approval, in the event that the Purchaser is otherwise entitled to the Milestone Shares, the Purchaser may elect to receive, by written notice to the Company, in lieu of the Milestone Shares, $30,000,000 in cash"
DamYankee
I appreciate your insight Mr. Greenwald but I disagree you on one matter. The following statement is inaccurate: "Finally, the filing notes that if TTP399 passes the trial phase G42 Investments will be given the right to purchase an additional USD 30 million in stock from vTv Therapeutics."
The correction is as follows from the License Agreement between Vtv Therapeutics & G42 Investments on page 11:
"the Company shall issue to the Purchaser as payment for the services provided by or on behalf of the G42 Counterparty under the Collaboration and License Agreement a number of newly-issued shares of Common Stock (such newly-issued shares, the “Milestone Shares”) equal to the quotient of (A) $30,000,000 divided by (B) the greater of (1) $1.20 and (2) the volume-weighted average price per share of Common Stock on the Nasdaq Capital Market as such daily volume-weighted average price per share is reported by Bloomberg L.P. (or, if such information is no longer reported by Bloomberg L.P., as reported by a comparable internationally recognized source reasonably determined by the Company) calculated for the twenty (20) consecutive trading days immediately following (but not including) the date the Company receives notice of the FDA Approval (rounded down to the nearest whole share); provided that, within thirty (30) days following the FDA Approval, in the event that the Purchaser is otherwise entitled to the Milestone Shares, the Purchaser may elect to receive, by written notice to the Company, in lieu of the Milestone Shares, $30,000,000 in cash"
Thank you very much for critique. I’m a lot of things, but an MBA is not one of them.
Additionally, does “second floor, James Hall” mean anything to you?